Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
6 hedge funds and large institutions have $443K invested in Altamira Therapeutics Ltd in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
100% more funds holding
Funds holding: 3 → 6 (+3)
11% less capital invested
Capital invested by funds: $497K → $443K (-$54K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$77.3K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$37.3K |
| 3 |
Morgan Stanley
New York
|
+$23K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.8K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$7.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $278K | +$7.46K | +11 | +3% |
|
|
2
Renaissance Technologies
New York
| $74K | +$77.3K | +114 | New |
|
|
3
Morgan Stanley
New York
| $42K | +$23K | +34 | +110% |
|
|
WS
4
Wedbush Securities
Los Angeles,
California
| $36K | +$37.3K | +55 | New |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $10K | +$10.8K | +16 | New |
|
6
JP Morgan Chase
New York
| $3K | +$3.39K | +5 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$1.36K | -2 | Closed |
|
CYTO Hedge Fund Activity: Q4 2019 in Review
6 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2019, worth a combined $443K — down 11% from $497K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CYTO positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $77.3K. The largest seller was UBS Group, exiting entirely with an estimated $1.36K sold.
- 6 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2019, up from 3 in Q3 2019.
- Funds reported $443K of Altamira Therapeutics Ltd stock for Q4 2019, down 11% quarter-over-quarter.
- 4 funds opened new Altamira Therapeutics Ltd positions in Q4 2019 and 1 closed out, a net change of +3 holders.
- The largest Altamira Therapeutics Ltd buyer in Q4 2019 was Renaissance Technologies, an estimated $77.3K added.
- The largest Altamira Therapeutics Ltd seller in Q4 2019 was UBS Group, an estimated $1.36K sold.
Based on aggregated 13F filings for Q4 2019.